Index RUT
P/E -
EPS (ttm) -1.05
Insider Own 3.60%
Shs Outstand 56.68M
Perf Week 1.22%
Market Cap 519.09M
Forward P/E -
EPS next Y -0.40
Insider Trans -0.86%
Shs Float 45.84M
Perf Month -4.91%
Income -68.00M
PEG -
EPS next Q -0.21
Inst Own 98.30%
Short Float / Ratio 19.63% / 19.72
Perf Quarter -15.02%
Sales 51.30M
P/S 10.12
EPS this Y 66.90%
Inst Trans -0.34%
Short Interest 9.00M
Perf Half Y -11.85%
Book/sh 4.94
P/B 1.84
EPS next Y 51.90%
ROA 147.50%
Target Price 13.40
Perf Year -9.71%
Cash/sh 2.94
P/C 3.10
EPS next 5Y -
ROE 220.80%
52W Range 8.76 - 12.03
Perf YTD -18.81%
Dividend -
P/FCF -
EPS past 5Y 25.40%
ROI -21.50%
52W High -24.27%
Beta 0.44
Dividend % -
Quick Ratio 7.80
Sales past 5Y 27.30%
Gross Margin -
52W Low 4.05%
ATR 0.29
Employees 111
Current Ratio 7.80
Sales Q/Q 23.40%
Oper. Margin -
RSI (14) 40.70
Volatility 2.32% 3.20%
Optionable Yes
Debt/Eq 0.00
EPS Q/Q 7.60%
Profit Margin -
Rel Volume 0.81
Prev Close 9.01
Shortable Yes
LT Debt/Eq 0.00
Earnings Aug 07 AMC
Payout 0.00%
Avg Volume 456.33K
Price 9.11
Recom 2.00
SMA20 -4.33%
SMA50 -5.78%
SMA200 -13.38%
Volume 367,605
Change 1.11%
Date
Action
Analyst
Rating Change
Price Target Change
May-23-22 Initiated
SVB Leerink
Outperform
$12
Nov-05-21 Upgrade
JP Morgan
Underweight → Neutral
$12
Sep-15-21 Downgrade
JP Morgan
Overweight → Underweight
$7
Aug-25-21 Downgrade
Morgan Stanley
Overweight → Underweight
$27 → $14
Aug-24-21 Downgrade
Cowen
Outperform → Market Perform
$42 → $14
Oct-14-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$32
Jul-07-20 Initiated
JP Morgan
Overweight
$29
Jun-15-20 Initiated
Morgan Stanley
Equal-Weight
$30
May-13-20 Initiated
Cowen
Outperform
$42
Jan-08-20 Reiterated
H.C. Wainwright
Buy
$25 → $30
Nov-06-19 Upgrade
Robert W. Baird
Underperform → Neutral
$22 → $18
Oct-29-19 Initiated
H.C. Wainwright
Buy
$25
Mar-29-18 Resumed
Piper Jaffray
Overweight
$45
Aug-17-17 Initiated
Evercore ISI
Outperform
$45
Jun-16-17 Initiated
Cantor Fitzgerald
Overweight
$55
May-11-17 Reiterated
Needham
Buy
$40 → $45
Dec-21-16 Initiated
Needham
Buy
$40
Nov-03-16 Initiated
Piper Jaffray
Overweight
Oct-12-16 Downgrade
Robert W. Baird
Neutral → Underperform
$19 → $24
Aug-03-16 Downgrade
BofA/Merrill
Neutral → Underperform
Show Previous Ratings
Sep-06-23 11:30AM
Aug-31-23 05:55PM
Aug-29-23 06:00AM
Aug-28-23 06:05AM
Aug-09-23 06:25AM
09:54AM
Loading…
Aug-08-23 09:54AM
Aug-07-23 05:25PM
04:25PM
04:05PM
Aug-01-23 10:00AM
Jul-24-23 06:00AM
Jul-03-23 09:00AM
Jun-08-23 11:14AM
Jun-07-23 11:30AM
May-18-23 01:50PM
03:41PM
Loading…
May-11-23 03:41PM
10:45AM
May-10-23 11:34AM
06:03AM
May-09-23 06:00PM
09:24AM
May-08-23 05:55PM
04:05PM
May-04-23 10:00AM
May-01-23 10:01AM
Apr-24-23 06:00AM
Apr-19-23 02:42PM
Apr-17-23 07:47AM
Apr-14-23 04:23AM
Apr-11-23 04:05PM
06:00AM
Loading…
Apr-10-23 06:00AM
Mar-31-23 12:41PM
11:30AM
Mar-30-23 05:22PM
11:30AM
Mar-29-23 11:30AM
Mar-10-23 06:56AM
Mar-08-23 02:50PM
Mar-02-23 06:00AM
Feb-28-23 02:17PM
01:33PM
Feb-27-23 06:15PM
04:05PM
11:26AM
09:00AM
Feb-23-23 07:46AM
Feb-21-23 06:00AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-09-23 06:00AM
Jan-09-23 06:00AM
Dec-25-22 09:39AM
Dec-07-22 11:30AM
Nov-22-22 04:15PM
Nov-18-22 06:00AM
Nov-11-22 08:20AM
Nov-08-22 08:34AM
Nov-07-22 05:45PM
04:05PM
Nov-02-22 04:30PM
Oct-31-22 06:00AM
Oct-27-22 10:02AM
Oct-26-22 10:02AM
Oct-25-22 06:00AM
Sep-28-22 06:00AM
Sep-20-22 09:36AM
Sep-19-22 02:28PM
07:22AM
06:00AM
Sep-08-22 11:30AM
Sep-06-22 06:00AM
Aug-14-22 08:06AM
Aug-05-22 11:53AM
Aug-04-22 07:25PM
04:05PM
Jul-28-22 06:00AM
Jul-27-22 10:01AM
Jul-26-22 10:01AM
08:11AM
Jul-18-22 10:20AM
Jul-14-22 06:04PM
(American City Business Journals)
08:58AM
Jul-13-22 05:29PM
04:25PM
04:05PM
08:00AM
Jul-11-22 05:07PM
(American City Business Journals)
Jun-06-22 08:38AM
May-13-22 01:57PM
May-06-22 04:15PM
May-05-22 07:15PM
04:05PM
May-04-22 06:30AM
May-02-22 06:30AM
06:00AM
Apr-26-22 03:01PM
Apr-13-22 06:30AM
Apr-12-22 06:30AM
Apr-11-22 06:30AM
Apr-06-22 06:00AM
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Sep 14 Sale 9.89 2,482 24,547 336,803 Sep 18 06:08 PM Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Aug 22 Sale 9.47 1,807 17,112 340,566 Aug 24 06:05 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Aug 11 Sale 9.99 2,322 23,197 349,746 Aug 15 06:09 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Jul 14 Sale 9.84 2,322 22,848 352,068 Jul 18 06:14 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Jun 14 Sale 10.69 2,322 24,822 354,390 Jun 16 06:14 PM Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Jun 08 Sale 11.13 1,790 19,923 352,833 Jun 12 06:08 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT May 15 Sale 11.26 2,322 26,146 367,172 May 17 06:17 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Apr 14 Sale 11.88 2,323 27,597 369,494 Apr 18 05:49 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Mar 14 Sale 10.32 2,323 23,973 371,817 Mar 16 07:04 PM Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Mar 09 Sale 10.20 4,000 40,800 360,190 Mar 13 05:57 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Mar 06 Sale 10.05 2,323 23,346 374,140 Mar 08 07:34 PM Winningham Rick E CHIEF EXECUTIVE OFFICER Dec 14 Sale 11.19 50,000 559,500 1,350,797 Dec 16 07:36 PM GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT Dec 01 Sale 10.73 2,084 22,361 313,520 Dec 05 05:59 PM Hindman Andrew A. SVP, CHIEF FINANCIAL OFFICER Nov 18 Sale 11.02 65,000 716,242 409,771 Nov 22 04:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite